DURHAM, NC – A young Durham biotechnology company has landed a grant of up to $1.5 million from the Michael J. Fox Foundation for Parkinson’s Research, according to a N.C. Biotechnology Center news release.
The company was established last year with the help of a loan from the center. The company is developing therapeutics for the treatment of Parkinson’s disease and depression and for protecting heart and other cells from dying as blood flow is restored after a heart attack, according to the release.
Its lead compounds, called DPI-289 and DPI-290, are aimed at treating Parkinson’s disease symptoms directly as well as controlling motor fluctuations associated with existing Parkinson’s treatments.